NCT06918808 - DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2026

Conditions

Perianal Fistula Due to Crohn's Disease

Interventions

BIOLOGICAL

DB-3Q

DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.

BIOLOGICAL

Placebo

0.9% NaCl

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center/NYPH, New York